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Admixture mapping based on recently admixed populations is a powerful method to detect disease variants
with substantial allele frequency differences in ancestral populations. We performed admixture mapping
analysis for systolic blood pressure (SBP) and diastolic blood pressure (DBP), followed by trait-marker
association analysis, in 6303 unrelated African-American participants of the Candidate Gene Association
Resource (CARe) consortium. We identified five genomic regions (P < 0.001) harboring genetic variants con-
tributing to inter-individual BP variation. In follow-up association analyses, correcting for all tests performed
in this study, three loci were significantly associated with SBP and one significantly associated with DBP
(P < 1025). Further analyses suggested that six independent single-nucleotide polymorphisms (SNPs) con-
tributed to the phenotypic variation observed in the admixture mapping analysis. These six SNPs were exam-
ined for replication in multiple, large, independent studies of African-Americans [Women’s Health Initiative
(WHI), Maywood, Genetic Epidemiology Network of Arteriopathy (GENOA) and Howard University Family
Study (HUFS)] as well as one native African sample (Nigerian study), with a total replication sample size of
11 882. Meta-analysis of the replication set identified a novel variant (rs7726475) on chromosome 5 between
the SUB1 and NPR3 genes, as being associated with SBP and DBP (P < 0.0015 for both); in meta-analyses
combining the CARe samples with the replication data, we observed P-values of 4.45 3 1027 for SBP and
7.52 3 1027 for DBP for rs7726475 that were significant after accounting for all the tests performed. Our
study highlights that admixture mapping analysis can help identify genetic variants missed by genome-
wide association studies because of drastically reduced number of tests in the whole genome.
INTRODUCTION
High blood pressure (BP) is common worldwide and is a major
risk factor for cardiovascular disease and mortality (1). Its
burden, however, is not equally shared across ethnically
diverse populations. In the USA, for example, the prevalence
of hypertension varies widely across ethnic populations,
between 27% in individuals of European ancestry to 40%
among people of African ancestry (2). Furthermore, the death
rate attributed to hypertension in 2004 was three times higher
in African-Americans than in European-Americans (3,4).
BP variation results from the combined effect of a complex
set of genetic and environmental influences, with genes account-
ing for 30–55% of the inter-individual variance (5). Recently,
several genome-wide association studies (GWASs) of BP
traits have reported new loci in samples from Asians, Europeans
and African-Americans (6–9). However, genetic studies of BP
in these populations have not identified loci common to both
ancestry groups, which may be attributable to population-
specific genetic variants, variation in allele frequencies, different
patterns of linkage disequilibrium (LD) across populations or
low statistical power due to limited sample size particularly in
African-Americans. Furthermore, no variants identified in the
previous GWAS of BP in African-Americans (6) were repli-
cated in a GWAS of BP in African-Americans in the Candidate
Gene Association Resource (CARe) study, highlighting the
challenges in searching for genetic variants in African ancestry
populations (10). Theoretical genetic studies suggest that admix-
ture mapping can be a powerful method to detect disease
variants in recently admixed populations, such as African-
Americans, when the parental populations show substantial
differences in disease prevalence (11–18). Admixture
mapping has identified loci or regions contributing to complex
traits such as prostate cancer, multiple sclerosis, obesity, focal
segmental glomerulosclerosis and blood lipids (19–24). To
date, several such studies have been conducted for hypertension
(25–27) and 6q24 and 21q21 have been reported to be associ-
ated with hypertension in both the Family Blood Pressure
Program study (27) and the Dallas Heart Study (26).
However, only weak association evidence was observed on
6q24 in an admixture mapping study by Deo et al. (25),
suggesting that further analysis is necessary. Here, we report
the findings of admixture mapping analysis for systolic BP
(SBP) and diastolic BP (DBP), followed by association analysis
in the regions identified using samples from the CARe consor-
tium, the largest African-American GWAS performed to date,
and provide the replication results of the most promising loci
in independent individuals of African descent.
RESULTS
Our discovery sample for admixture mapping analysis
included up to 6303 unrelated African-Americans from five
of the nine CARe participating cohorts: Atherosclerosis Risk
In Communities (ARIC), Coronary Artery Risk Development
in Young Adults (CARDIA), Cleveland Family Study (CFS),
Jackson Heart Study (JHS) and Multi-Ethnic Study of Athero-
sclerosis (MESA), which were genotyped using the Affyme-
trix 6.0 array. The cohort-specific sample characteristics are
presented in Supplementary Material, Table S1. For CFS
and JHS, if more than one founder was available in a
family, we included the founders. Otherwise, only one ran-
domly selected offspring in each family was included in the
analysis. The correlation between SBP and DBP was 0.71.
We analyzed the data using ADMIXPROGRAM (18) first.
Using 3230 ancestry informative markers (AIMs; see
Materials and Methods), we estimated that the number of gen-
erations since the occurrence of population admixture was 10
in this African-American sample, consistent with other admix-
ture estimates in African-Americans (26–28). The estimated
average European ancestry in this sample was 18.9+ 11.6%.
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The correlations between average African ancestry and SBP
and DBP were 0.056 and 0.08 (P , 0.0001 for both), respect-
ively. Using the estimated marker-specific ancestry, we per-
formed quantitative admixture analysis for SBP and DBP.
Supplementary Material, Figure S1 presents the 2log10(P)
values testing for the association of local African ancestry
with SBP and DBP at the 3230 AIMs after adjusting for
global ancestry. We did not observe any region reaching
genome-wide significance. For follow-up studies, we chose
three top peaks of association between local ancestry and
SBP and three top peaks of association of local ancestry and
DBP with P , 0.001 (Table 1). At each peak, we defined
the target region as comprising the locus that is within 1 unit
drop of 2log10(P) from the peak signal. The region on
chromosome 2 showed overlap for SBP and DBP, with
the maximum 2log10(P) occurring at the same marker
(Table 1). When the same data were analyzed using STRUC-
TURE (28,29), we obtained almost identical results (Sup-
plementary Material, Fig. S2).
We then searched the variants associated with SBP and
DBP in the five uniquely identified regions using the single-
nucleotide polymorphisms (SNPs) genotyped on the Affyme-
trix 6.0 array. Since only variants with substantial allele fre-
quency differences in ancestral populations can be detected
by admixture mapping, we sought SNPs with allele frequency
differences larger than 0.2 between HapMap the Yoruba
people of Ibadan, Nigeria (YRI) and the centre d’Etude du
polymorphisme humain from Utah (CEU) samples. The
number of SNPs with a d-value of .0.2 was listed in
Table 1. We then tested the strength of association between
these SNPs and both SBP and DBP. The Q–Q plots for associ-
ation for SBP and DBP (Fig. 1A and B) demonstrated substan-
tial deviation from the null hypothesis that none of these
variants are associated with BP after controlling for population
stratification. To determine which SNPs were statistically sig-
nificant in our analysis, we estimated the total number of inde-
pendent tests in both the admixture mapping and the SNP
association tests. Since the locus-specific ancestries are depen-
dent and the strength of dependence is determined by the
population admixture history, we estimated the total number
of tests we performed in this study. It was reported that the
total number of independent tests in the genome for testing
local ancestry in the African-American population is 1000
(15,18). Since the SNPs selected in association tests are also
dependent, we then calculated the number of independent
tests in each region using the method of Li and Ji (30) and
these numbers are presented in Table 1. Thus, the total
number of tests in admixture mapping and association tests
together was 4738 and the corresponding P-value to claim
statistical significance was set at 1.06 × 1025. After adjusting
for the number of SNPs tested, we identified two different loci
(on 2q21-24 and 21q21) significantly associated with SBP and
one locus (on 5p13-11) associated with DBP (Table 2 and
Supplementary Material).
We next tested whether the most significant SNP in each
region accounted for the observed effect in admixture
mapping by adjusting for the most significant SNP in each
region in the linear regression equation for modeling local
ancestry association (see Materials and Methods). For DBP,
after adjusting for the most significant SNP (rs4957217 in
the DAB2 region on 5p13-11), we observed a substantial
reduction in the association evidence between local European
ancestry and DBP, although it remained significant (P ¼
0.001; Fig. 2). To search for additional variant(s) contributing
to these effects, we performed conditional association analyses
for 1535 SNPs in the region of 1 unit drop from the peak
signal (see Table 1 for the defined region) while adding
rs4957217 as a covariate in the regression model. We
ranked the P-values and identified two additional SNPs,
rs7726475 and rs7737481, as the most significant (P ≤
0.0003). After adjusting for all three SNPs, the association
between local African ancestry and DBP in this region was
no longer significant (P ¼ 0.14, Fig. 2), suggesting that these
three SNPs adequately account for the observed association.
Notably, these three SNPs are not in LD (r2 ≤ 0.006) with
each other in the sample. Similar analysis was performed on
the chromosome regions of interest for SBP. We identified
three independent SNPs on chromosomes 2 and 21 that con-
tribute to the observed association with SBP (Table 2 and Sup-
plementary Material, Figs S3 and S4). We did not observe any
Table 1. The most significant chromosome regions showing the association of SBP and DBP with African Ancestry
Region (Mb)a The most
significant SNP
BETAb SE P-valuec Number of SNPs




1q41-42 217–229 rs6686694 3.7 1.06 4.6 × 1024 1218 581
2q21-24 132.6–164.9 rs2166488 23.86 1.04 2.1 × 1024 2994f 1362
21q21 26.7–36.0 rs2833563 3.82 1.08 4.0 × 1024 1181 591
DBP
2q22-24 143.4–163.3 rs2166488 2.16 0.60 2.8 × 1024 2994f 1362
5p13-11 31.9–51.2 rs35389 22.21 0.60 2.2 × 1024 1535 742
17q11 14.8–28.7 rs8066682 21.97 0.59 8.2 × 1024 851 462
aRegion is defined as the 1-unit drop region from the 2log10(P) value of the most significant SNP.
bPositive BETA value indicates that African ancestry increase the BP level and negative BETA indicates that European ancestry increase the BP level.
cP-value is two-sided.
dThe SNPs with d . 0.2 were selected for follow-up association tests and these SNPs were available in Affymetrix 6.0 array in each region.
eThe number of independent tests calculated by the method of Li and Ji (30).
fThe number of SNPs was calculated for the region 132.6–163.4 Mb on chromosome 2.
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SNP on the regions within chromosomes 1 and 17 with a
P-value of ,1.06 × 1025.
We next calculated how much of BP variation could be
explained by these six SNPs (starred in Table 2) using an addi-
tive genetic model. Indeed, 1.21 and 1.16% of inter-individual
variation in SBP and DBP, respectively, can be explained by
the six SNPs in aggregate. Furthermore, we repeated the single
SNP association analysis by adding these six SNPs as covariates
in the regression models demonstrating no substantial deviation
from expectations as observed in the Q–Q plots of SBP and
DBP in the three regions (Fig. 1C and D). Upon doing so, the
genome inflation factor (lambda, l) was close to 1.0.
Independent replication of identified SNPs
We next sought to replicate the CARe African-American BP
associations at the six SNPs in five independent cohorts:
Maywood, Howard University Family Study (HUFS),
GENOA, Women’s Health Initiative (WHI) and Nigeria (see
Supplementary Material for study details). All these cohorts
recruited African-American except the Nigeria cohort, which
was comprised of native Africans from Nigeria. All the
five cohorts have been genotyped with the Affymetrix 6.0
array.
In cohort-specific analysis, only SNP rs7726475 was signifi-
cantly associated with both SBP and DBP in WHI (P , 0.002)
after adjusting for 12 tests (six SNPs and two traits, Table 3).
Table 4 presents the meta-analyses for two sets of populations,
one that includes the replication cohorts only and the other
also including the CARe derivation set. Again, rs7726475
was significant in the meta-analysis of replication cohorts
for both SBP and DBP (P ¼ 0.0015). If only the four
African-American replication cohorts were included, the
P-values were further improved to 0.0008 for SBP and
0.0013 for DBP, respectively. The P-value of this SNP in
the meta-analysis including CARe and all replication cohorts
was 8.85 × 1027 for SBP and 3.63 × 1026 for DBP, respect-
ively, which remained significant after adjusting for multiple
comparisons.
In the above admixture mapping and association analyses,
we only included unrelated individuals and removed 1170
related individuals in CARe JHS and CFS cohorts (see
Materials and Methods). After including these 1170 individ-
uals, the P-values for rs7726475 in CARe improved to
3.16 × 1025 and 4.62 × 1025, with final P-values from com-
bining CARe and replication samples of 4.45 × 1027 and
7.52 × 1027, for SBP and DBP, respectively. The P-values
were further improved to 2.17 × 1027 for SBP and 6.28 ×
1027 for DBP when meta-analysis was restricted in
African-American samples. We did not observe any other
SNPs reaching significance upon combining all cohorts. Our
meta-analysis did not provide evidence of heterogeneity
across the replication cohorts for rs7726475 (P . 0.30,
Table 4). We did observe evidence of heterogeneity for
SNPs other than rs7726475, however, when combining all
CARe and replication cohorts together (Table 4).
Figure 1. Q–Q plots for SNPs in the five genomic regions with allele frequency difference larger than 0.2 between YRI and CEU HapMap samples. (A and B)
SBP and DBP without adjusting for the associated SNPs in the linear regression analysis in each region, respectively; (C and D) SBP and DBP after adjusting for
the associated SNPs on chromosomes 2, 5 and 21 in the linear regression analysis in each region, respectively. After adjusting for associated SNPs, we did not
observe any significant departure of the Q–Q plot from expectations. The two gray lines along the straight diagonal line refer the 95% confidence band.
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DISCUSSION
Admixture mapping can supplement traditional genome-wide
association analyses in the search for genetic variants under-
lying complex traits. We performed admixture mapping analy-
sis using the largest African-American GWAS for SBP and
DBP performed to date, followed by association analysis,
and identified six independent SNPs accounting for the BP
signals observed in admixture mapping analysis. Replication
analysis in four independent African-American cohorts and a
Nigerian cohort, with a total replication sample size of
11 882, identified rs7726475 as associated with both SBP
and DBP. The combined P-values in meta-analysis including
both CARe and replication cohorts were 4.45 × 1027 for
SBP and 7.52 × 1027 for DBP, reaching the statistical signifi-
cance level after adjusting for all tests performed (P , 1.06 ×
1025). The similar P-values reflect the strong correlation
between SBP and DBP (r2 ¼ 0.594). However, only WHI
was individually able to replicate the association evidence
for rs7726475. The inflation factor for WHI is 1.018 for
both SBP and DBP, in which suggests that the association in
WHI is not due to population structure. We then calculated
the power given the replication sample sizes. We assumed
the variances attributed to rs7726475 for SBP and DBP to
be 0.24 and 0.19%, respectively. These variances were esti-
mated from CARe discovery data, which may be overesti-
mated in the general population. Except for the WHI, the
power to replicate rs7726475 ranged from 22.1 to 39.3% in
the remaining four replication cohorts (Supplementary
Material, Table S3), suggesting that the sample sizes of
these four cohorts were underpowered. Although the effect
sizes were smaller than estimated in CARe, three of the four
African American cohorts (Maywood, HUFS and WHI)
demonstrated a direction of the effect that was consistent
with CARe, (Table 3). GENOA had opposite direction of
effect for both SBP and DBP but the estimates were not stat-
istically significant. Using the effective sizes obtained from
CARe, we had less than 30% power to detect rs7726475 in
GENOA and the power was reduced to less than 14% when
using the effective sizes from WHI. The effect size direction
in the Nigeria cohort was also opposite in direction, but the
estimate was not statistically significant. The risk allele fre-
quency of rs7726475 was 2% in the Nigeria sample, 6% in
African-American and 34.5% in HapMap CEU samples,
suggesting that the European allele was responsible for the
association evidence. This is consistent with our observation
that European ancestry at the locus on 5p13-11 increases
both SBP and DBP (Table 1). Thus, the non-significant oppo-
site direction of rs7726475 in Nigeria is quite possible. Our
results suggest that SNP rs7726475 is in LD with a causal
variant. Therefore, different LD patterns may explain the
different directional effects in African-Americans and native
Africans. When we dropped the Nigeria cohort in the
meta-analysis of replication cohorts, the P-values for SNP
rs7726475 improved to 0.0008 and 0.0013 for SBP and
DBP, respectively, and the combined CARe and replication
African-American cohorts P-values improved to 2.17 × 1027
for SBP and 6.28 × 1027 for DBP.
Our results indicate that the findings for rs7726475 are
replicated in African-Americans. The annotated genes near
the significant SNP rs7726475 include natriuretic peptide
receptor c (NPR3), chromosome 5 open reading frame 23
(C5orF23) and activated RNA polymerase II transcription
cofactor (SUB1). NPR3 belongs to the family of natriuretic
peptides, which are known to elicit a number of vascular,
renal and endocrine effects that are important in the mainten-
ance of BP and extracellular fluid volume. These effects are
mediated by a specific binding of peptides to cell surface
receptors in the vasculature, kidney, adrenal and brain (31).
NPR3 has also been reported to have an important role in
BP regulation in human and animal models (32–35). Thus,
NPR3 is an excellent candidate gene for knockout studies
and follow-up resequencing studies to identify functional var-
iants with potentially large effects on BP.
In the CARe admixture mapping analysis, we replicated the
21q21 region reported in previous admixture mapping studies
of hypertension in African-American populations (26,27). We
observed three additional regions (1q41-42, 2q21-24, 5p13-11)
showing suggestive evidence. In the follow-up association
analysis, we observed significant evidence of genetic influ-
ences on SBP and DBP for three SNPs on chromosomes
2q21-24 and 21q21. Replication analyses, however, failed to
Table 2. Significant SNPs in regions detected by admixture mapping for SBP and DBP
CHR SNP Base pair
position
Nearby genes SBP DBP
A1 A2 A1_FREQ BETA SE SBP_P BETA SE DBP_P
2 rs2450a 153292667 FMNL2, ARL6IP6,
PRPF40A
G T 0.06253 3.117 0.7497 3.26 × 1025 1.607 0.4283 1.77 × 1024
2 rs295796 157461617 T A 0.4579 1.579 0.3566 9.65 × 1026 0.6791 0.2035 8.53 × 1024
2 rs295813a 157472109 GLANT5 G A 0.4045 1.807 0.3723 1.24 × 1026 0.7997 0.2124 1.68 × 1024
2 rs1033225 157514397 T C 0.3989 1.731 0.3712 3.16 × 1026 0.7588 0.2116 3.39 × 1024
2 rs1033224 157514699 A T 0.4849 1.6 0.3586 8.29 × 1026 0.6965 0.2049 6.82 × 1024
5 rs7726475a 32611671 SUB1, NPR3,
C5orf23
A G 0.06633 2.965 0.726 4.49 × 1025 1.503 0.4148 2.93 × 1024
5 rs7737481a 37818160 C9 G A 0.3048 20.5672 0.3911 1.54 × 1021 20.8779 0.2228 8.23 × 1025
5 rs4957217a 39712034 DAB2 T C 0.205 21.455 0.4411 9.78 × 1024 21.125 0.251 7.59 × 1026
21 rs2236611a 32607151 URB1, MRAP T C 0.1687 22.302 0.4909 2.79 × 1026 21.011 0.2806 3.18 × 1024
The number of multiple comparisons was determined by the number of SNPs tested in each region. The effect size is presented in terms of the reference allele A1.
The four SNPs at 157 Mb on chromosome 2 are in strong LD with one another. P-values in bold are significant after adjusting for multiple tests.
aThe independent SNPs that can explain the association evidence in admixture mapping analysis.
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confirm these associations. Replication was accomplished
mostly by the WHI associations, which had large sample
size of 8300 with enough power to identify associations of
small magnitude as expected for common variants. As WHI
includes women only, we performed sex-specific analysis in
the CARe samples. These results did not reveal sex-specific
association for these SNPs (Supplementary Material,
Table S4).
With a replication sample size of 11 882 individuals, we had
93% power to detect a quantitative trait locus accounting for
0.1% of the trait variance at a two-tailed significance level of
0.05. Thus, our combined replication sample size should have
adequate power to replicate the evidence observed in CARe.
As such, the SNPs identified on chromosomes 2q21-24 and
21q21 may represent false-positive associations. However,
several factors may limit our capacity to replicate true associ-
ations. First, we assumed that both SBP and DBP can be accu-
rately measured. Second, we assumed that there were no
heterogeneities across samples, although several sources of het-
erogeneity exist. For example, our samples were recruited from
different geographical regions or countries and the environ-
mental factors contributing to BP variation can be substantially
different, as indicated in Supplementary Material, Table S1. In
particular, the Nigerian cohort may have substantially different
environmental influences relevant to BP compared with the
African-American cohorts. Furthermore, the prevalence of anti-
hypertensive medication use in the Maywood cohort was only
1%, which is substantially lower than that in the general
African-American population. In addition, WHI includes
African-American post-menopausal women only. In the WHI
data, global African ancestry was not correlated with either
SBP or DBP [P . 0.37 for the first principal component (PC)
and .0.15 for the first 10 PCs]. The phenotypic heterogeneity
may reduce the power to replicate findings substantially.
Third, our reported association variants in CARe are for ancestry
informative SNPs that are likely in LD with true unknown
Figure 2. Change in DBP association evidence in admixture mapping analysis
on chromosome 5 with, and without, adding associated SNPs. Addition of SNP
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genetic variants. Fourth, it is possible that there may be more
than one functional variant underlying BP variation in these
regions, as suggested by our finding that more than one SNP
was required to account for the association evidence in a
number of loci for our admixture mapping analysis. Thus, mul-
tiple variants can make replication studies more challenging
(36). Fifth, due to the evolution process, it is also possible that
there are many population-specific rare variants in these
regions contributing to BP variation, reflecting allelic hetero-
geneity. In this case, replication studies may fail because of
differences in the influence of rare variants. A resequencing
analysis aimed at detecting the population-specific rare variants
in these regions and a follow-up association analysis in a large
cohort may be needed to detect the true variants underlying
BP variation. Lastly, the effective sizes observed in CARe for
these SNPs may have been overestimated because of a
‘winner’s curse’; consequently, our power calculation may be
still overly optimistic. Thus, the association evidence on
chromosomes 2 and 21 need further studies.
Our failure to replicate the loci on chromosomes 2 and 21
emphasizes the challenges to the identification of genetic var-
iants underlying BP. Compared with the recent GWAS of BP
in populations of European descent (7,8), our discovery and
replication sample sizes are still relatively small. The
genetic variation covered by the current commercial chips is
still lower in non-European populations such as
African-Americans. Therefore, many factors contribute to
the difficulty identifying consistent evidence of association
between genetic variants and BP. We believe that it is worth-
while to conduct GWAS of BP variation including admixture
mapping in larger samples in African-Americans.
In summary, we have performed the largest admixture
mapping and association study of BP in African-Americans
to date. Our study reveals that admixture mapping analysis
can help identify genetic variants with substantial allele fre-
quency differences in ancestral populations. Specifically, we
have shown that SNP rs7726475, located near SUB1 and
NPR3, is significantly associated with both SBP and DBP in
African-Americans. This region deserves investigation,
including additional replication studies.
MATERIALS AND METHODS
Study samples
The study was approved by the Institutional Review Board
(IRB) at Case Western Reserve University. The CARe Study
is described in detail elsewhere (37). CARe includes nine
cohorts, five of which contributed African-American samples
for this analysis. The five African-American cohorts are:
ARIC, CARDIA, CFS, JHS and the MESA. The unrelated
samples from these five cohorts were used in the admixture
mapping analysis and the follow-up association analysis. For
CFS and JHS, if more than one of the founders were available
in a family, we included the founders. Otherwise, only one off-
spring was randomly selected in each family. As a result, we
excluded 1170 related individuals in the admixture mapping
and the follow-up association analysis. However, these indi-
viduals were eventually added back for association analysis.
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GENOA and WHI cohorts. A detailed description of each
cohort can be found in the Supplementary Material.
Adjusting for SBP and DBP
For individuals reporting the use of antihypertensive medi-
cations, BP was imputed by adding 10 and 5 mmHg for SBP
and DBP (38), respectively. This imputation method has
been used widely (7,8). Continuously measured values of
DBP and SBP were adjusted for age, age2, body mass index
(BMI) and gender in generalized linear models. Residuals
were calculated in each cohort separately and were then com-
bined for admixture mapping analysis as well as genotype–
phenotype association analysis.
Admixture mapping analysis
We calculated the d values for the SNPs available in the Affy-
metrix 6.0 array. The d-value is defined as the absolute differ-
ence of an allele frequency between HapMap CEU and YRI
samples. We divided the 23 autosomes into 1 Mb bins and
then selected ancestry informative SNPs as the SNPs with
the largest d in each bin. We selected an AIM panel that
included 3230 markers from the 854 893 SNPs passing
quality controls (QCs). We examined Hardy–Weinberg equi-
librium (HWE) of these 3230 SNPs for possible genotyping
errors and background LD which may violate the assumption
in admixture mapping analysis (18). All the 3230 SNPs are in
HWE and not in LD in HapMap CEU and YRI data. Among
the AIMs, more than 98.6% markers have a d-value of .0.4
(Supplementary Material, Table S5). The average Shannon
information content (SIC) for the AIMs we selected was
0.849, suggesting that we generally have very good coverage
using these AIMs. We plotted the SIC across the genome
(Supplementary Material, Fig. S5).
These SNPs were entered in the hidden Markov model to esti-
mate the marker locus-specific ancestry in African-Americans
based on the expectation-maximization (EM) algorithm using
the software ADMIXPROGRAM (18). This method directly
maximizes the likelihood function through an EM iterative
algorithm and allows consideration of uncertainty of marker
allele frequencies in the parental populations. We assumed
that there were two parental populations for the
African-Americans. To examine whether our method would
yield reliable parameter estimations, we ran ADMIXPRO-
GRAM twice, one without using any ancestral population infor-
mation and the other using the allele frequencies of HapMap
CEU and YRI as the initial values. We found both methods gen-
erate the same parameter estimate values. Furthermore, we com-
pared the estimated allele frequencies in ancestral African and
European populations to those in HapMap YRI and CEU data
and found high correlation
(Supplementary Material, Figs S6 and S7), indicating that our
results are robust and reliable. We further re-estimated marker-
specific ancestry using STRUCTURE (28,29), a
Bayesian approach, and compared the results based on ADMIX-
PROGRAM and STRUCTURE. STRUCTURE was run under
the linkage model without haplotype phase information, with
10 000 burn-in iterations followed by an additional 10 000 iter-
ations.
We then performed linear regression analysis similar to
Basu et al. (23). Specifically, let yi be the residual of individual
i after adjusting for age, age2, BMI and gender. Let Aij be the
African ancestry at the jth AIM and Ai be the average African
ancestry of individual i. Aij was estimated by ADMIXPRO-
GRAM and Aiwas calculated as the mean of Aij for all
AIMs. We performed the linear regression analysis as
yi = b0 + b1Ai + b2(Aij − Ai) + 1i and test the null hypoth-
esis: b2 ¼ 0, which was used to assess statistical significance
in admixture mapping. Here, yi is the residual of SBP or
DBP for the ith individual. We considered a P-value of
,0.001 for testing the null hypothesis: b2 ¼ 0 as suggestive
evidence of association in admixture mapping analysis, and
we further defined a region of admixture mapping as compris-
ing the locus that is within the 1 unit drop of 2log10(P) from
the peak signal.
Single SNP association and testing SNPs accounting
for admixture mapping evidence
To identify SNPs contributing to the association evidence
observed in the admixture mapping analysis, we next per-
formed SNP association analysis assuming an additive
model in linear regression using PLINK (39) in regions with
P-values of ,0.001. In addition, we added each individual’s
average European ancestry Ai into the regression model to
account for the effect due to population structure. Since only
the SNPs with substantial allele frequency differences in
ancestral populations can possibly contribute to the association
evidence in admixture mapping analysis, we tested only the
SNPs with a d-value of .0.2 in these regions. To determine
whether an SNP is significant, we calculated the total
number of tests in our study by adding the number of indepen-
dent tests in admixture mapping and the number of indepen-
dent tests in the regions we identified. Since the ancestries
across the genome are dependent, the total number of indepen-
dent tests in admixture mapping analysis is suggested to be
1000 (15) for African Americans, which is also consistent
with a simulation study (18). Since the SNPs with a d-value
of .0.2 are also correlated, we calculate the number of inde-
pendent tests in each region separately using the method by Li
and Ji (30). The significant SNPs were defined as those sur-
vived after the Bonferroni correction of the total number of
tests in both admixture mapping and SNP analysis.
To examine whether one or several SNPs were able to
account for the evidence observed in admixture mapping
analysis, we adjusted for these SNPs in the regression model
and evaluated the significance of testing b2 ¼ 0. No signifi-
cance suggests that the SNPs are able to account for the evi-
dence observed in admixture mapping analysis.
Analysis of adding back 1170 related individuals
In admixture mapping and follow-up association analysis, we
removed 1170 related individuals from CFS and JHS cohorts.
We added them back in our final analysis for SNP rs7726475.
In this analysis, the first 10 PCs were calculated and included
in the model testing genotype–phenotype association in each
cohort separately. This procedure may control for any popu-
lation structure due to factors other than African-European
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admixture. The PCs were calculated based on selected AIMs.
We tested the association of rs7726475 and SBP and DBP by
linear regression with an additive genetic model using PLINK
for all the cohorts except for CFS, in which association was
tested using a linear mixed-effect (LME) model that accounted
for family structure (40). The results for JHS for applying
PLINK and LME were almost identical (10). Meta-analysis
of the results was then carried out using the inverse-variance
weighting method in METAL (41).
Replication analysis
In each replication cohorts, SBP and DBP were imputed in the
same way as in CARe data, in which 10/5 units was added to
SBP/DBP if a subject was under medication treatments. In
each cohort, SNP association analysis was performed assum-
ing an additive model in linear regression using PLINK (39)
for the SNPs carried forward to the replication analysis,
adjusting for age, age2, BMI and gender. Since all the replica-
tion cohorts have been genotyped with the Affymetrix 6.0
array, we calculated the first 10 PCs using all the SNPs after
QCs. These 10 PCs were added into the linear regression
model to control the effect by population structure.
Meta-analysis of results was then carried out using the inverse-
variance weighting method in METAL (41).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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